Trials / Completed
CompletedNCT06619314
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
A Three-Part Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor on the Single-Dose Pharmacokinetics of MK-1084 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Calderasib | Oral Tablet |
| DRUG | PPI | Oral Capsule |
Timeline
- Start date
- 2023-09-20
- Primary completion
- 2023-11-25
- Completion
- 2023-11-25
- First posted
- 2024-10-01
- Last updated
- 2026-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06619314. Inclusion in this directory is not an endorsement.